-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 8, 2021, Anke Biological disclosed its annual report.
In 2020, it will realize total operating income of 1.
7 billion (-0.
7%), and net profit of 360 million (+188.
4%) attributable to the parent.
The company's gross profit margin will be 78.
8% (+0.
7%).
), the net profit margin is 20.
4% (+13.
9%)
.
At the same time, the performance forecast for the first quarter of 2021 is disclosed.
From the perspective of business structure, "genetically engineered drugs" are the main source of business income for companies
.
The revenue and net profit of the main product recombinant human growth hormone products increased significantly year-on-year, which led to a substantial increase in the consolidated net profit index
It is worth noting that according to the remuneration of directors and executives announced in the annual report, Song Lihua, chairman and president of Anke Biotech, became the company’s highest-paid manager with a pre-tax income of 1.
26 million.
His younger brother Song Liming, vice chairman of Anke Biotech The pre-tax income is also 525,000 yuan
.
Of course, the annual salary is second.
And all this wealth is inseparable from Song Lihua's legendary experience
.
Song Lihua, born in 1957, started his career as a private teacher in the city of Dangtu County, Anhui Province, when he was 19 years old
.
In 1977, the college entrance examination was restored, and Song Lihua took the opportunity to be admitted to the Department of Plant Protection of Anhui Agricultural University
.
After obtaining a master's degree in plant virology in 1984, he entered the Anhui Provincial Institute of Biology, and then went to the Hannover Institute of Immunology in Germany for further study, engaged in "animal gonadotropin monoclonal antibody" research, and pursued a doctorate degree
.
In 1990, he gave up the opportunity to work overseas, returned to China to provoke the important task of rejuvenating the country through science and technology, undertook a number of national and provincial key scientific research projects, and developed "human interferon alpha monoclonal antibody affinity chromatography gel" and "recombinant human interferon alpha 2b" ", "recombinant human growth hormone" and other internationally advanced cell and genetic engineering products
.
In 1994, in order to deepen the science and technology system, led by Song Lihua Institute of Anhui Province as a national research institutes, he founded the Anhui Anke Biotechnology Co.
, Ltd
.
Start the journey of wealth creation
Relying on the success of Song Lihua’s early research project, Song Lihua took the initiative to go to Shanghai to promote his results to manufacturers of interferon.
The product was greatly appreciated and was soon widely used in China.
In only two years, it achieved a profit of 60 million yuan, which is also Song Lihua’s decision.
The first pot of gold made
.
The so-called "brothers fighting tigers, fighting fathers and sons", Song Lihua also appointed his younger brother Song Liming as the company's deputy general manager at the beginning of the establishment of Anke Biological.
The two brothers are in charge of internal affairs and external affairs; one is engaged in research and the other is engaged in sales
.
In the next 10 years, Anke Biological has independently researched and developed more than 10 new national-level drugs.
Today's Anke Biology relies on self-developed, highly profitable genetically engineered interferon α2b and genetically engineered recombinant human growth hormone and other high-tech products.
Anke Biology maintains a high-speed growth of 30-40% every year, with abundant cash flow.
Dividends are also considerable
.
At the end of October 2009, it successfully opened the gong on the GEM and became one of the first 28 listed companies
During the period, Anke Biological, in order to expand its own product chain and a strategic plan for stable and sustainable development, reopened the road of industrial mergers and acquisitions in 2014
.
Co-funded the establishment of Anhui Xinhuakun Bioengineering Co.
With the rapid development of the global tumor market, nearly half of the top ten drugs sold globally are targeted anti-tumor drugs.
Information Sources:
1.
3.
"Leading precision medicine from biopharmaceutical to biomedicine-Interview with Song Lihua, Chairman of Anke Biotech" - http:// 4.
https:// Editor in charge | Penicillin
Disclaimer: The opinions of this article only represent the author, not the position of Yaozhi.
com.
Welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article
.
